TB-500 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
=== Structure === The plantar fascia is made up of predominantly longitudinally oriented collagen fibers. There are three distinct structural components: the medial component, the central component (plantar aponeurosis), and the lateral component (see diagram at right). The central component is the largest and most prominent.
== Awards and honours == 2007 Donald F. Steiner Award for Outstanding Diabetes Research, University of Chicago 2008 Prix Galien Canada for Outstanding Pharmaceutical Research 2009 Clinical Investigator Award, Endocrine Society 2012 Claude Bernard Prize, European Association for the Study of Diabetes 2012 Fellow of the Royal Society of Canada 2013 Oon International Award for Preventative Medicine, University of Cambridge 2014 Banting Medal for Scientific Achievement, American Diabetes Association 2014 Manpei Suzuki Foundation International Prize for Diabetes, Japan 2015 Fellow of the Royal Society 2015 Officer of the Order of Canada 2017 Rolf Luft Award in Endocrinology and Diabetes Research, Karolinska Institute 2017 Harrington Prize for Innovation in Medicine, American Society for Clinical Investigation and the Harrington Institute (co-recipient with Joel Habener and Jens Juul Holst) 2019 Harold Hamm International Prize for Biomedical Research in Diabetes 2019 Novo Nordisk Foundation and European Association for the Study of Diabetes Prize for Excellence in Diabetes Research (watch the mini documentary about Drucker produced by the Novo Nordisk Foundation for the occasion) 2019 Lifetime Achievement Award, Helmholtz Diabetes Centre, Germany 2020 John Baxter Award for Entrepreneurship, Endocrine Society 2020 Transatlantic Medal, Society for Endocrinology 2020 Warren Alpert Foundation Prize for Biomedical Research (co-recipient with Joel Habener and Jens Juul Holst) 2021 International Member, National Academy of Sciences 2021 Canada Gairdner International Award (co-recipient with Joel Habener and Jens Juul Holst) 2022 Inductee of the Canadian Medical Hall of Fame 2023 Wolf Prize in Medicine 2023 International Member of the National Academy of Medicine 2023 VinFuture Prize for Innovators with Outstanding Achievements in Emerging Fields (co-recipient with Joel Habener, Jens Juul Holst and Svetlana Mojsov) 2024 Princess of Asturias Award for Technical and Scientific Research (co-recipient with Jeffrey M. Friedman, Joel Habener, Jens Juul Holst and Svetlana Mojsov) 2024 Time100 Most Influential People and Time100 Health 2024 Golden Plate Award, American Academy of Achievement 2024 Fred Conrad Koch Lifetime Achievement Award, Endocrine Society 2024 TOPS Research Achievement Award, The Obesity Society 2025 Warren Triennial Prize, Massachusetts General Hospital (co-recipient with Joel Habener and Svetlana Mojsov) 2025 BBVA Foundation Frontiers of Knowledge Award in Biology and Biomedicine (co-recipient with Joel Habener, Jens Juul Holst and Svetlana Mojsov) 2025 Solomon A. Berson Award, American Physiology Society 2025 Breakthrough Prize in Life Sciences (co-recipient with Joel Habener, Jens Juul Holst, Svetlana Mojsov and Lotte Bjerre Knudsen) 2026 Governor General's Innovation Award
For its 1994 reunion, King Crimson reassessed both the mid-1970s and 1980s approaches in the light of new technology, intervening music forms such as drum and bass and techno, and further developments in industrial music, as well as expanding the band's ambient textural content via Fripp's Soundscapes. The 2013 version of the band returned, for the most part, to the band's 1960s and 1970s influences and repertoire but addressed them via current technology and rearrangements suited to a larger ensemble of more experienced musicians, while also incorporating the new standard tuning used by Fripp since 1984.
Sources: en.wikipedia.org
Mifamurtide (trade name Mepact, marketed by Takeda) is a drug against osteosarcoma, a kind of bone cancer mainly affecting children and young adults, which is lethal in over half of cases. The drug was approved in Europe in March 2009.
All chemical elements derive from stellar nucleosynthesis except for hydrogen and some helium and lithium. Basic chemical ingredients of life – the carbon–hydrogen molecule (CH), the carbon–hydrogen positive ion (CH+) and the carbon ion (C+) – can be produced by ultraviolet light from stars. Complex molecules, including organic molecules, form naturally both in space and on planets. Organic molecules on the early Earth could have had either terrestrial origins, with organic molecule synthesis driven by impact shocks or by other energy sources, such as ultraviolet light, redox coupling, or electrical discharges; or extraterrestrial origins (pseudo-panspermia), with organic molecules formed in interstellar dust clouds or in the solar nebula accumulating onto the planet.
=== Thorium-230 === 230Th is a radioactive isotope of thorium that can be used to date corals (uranium-thorium dating) and determine ocean current flux. Ionium (symbol Io) was the name given early in the study of radioactive elements to the 230Th isotope produced in the decay chain of 238U before the nature of isotopes was fully realized. The name is still used in ionium–thorium dating, another dating method using this isotope.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.